Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OlympiA: Olaparib in gBRCA1/2 Mutated High Risk HER2 Negative Primary Breast Cancer
NCT02032823Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Apr 2014
- Primary completion
- Mar 2020
- Modality
- Small Molecules
- Countries
- 24
01
Overview
Phase 3, randomised, double-blind trial in breast cancer comparing Olaparib with Placebo (2 arms). Primary endpoint: Invasive Disease Free Survival. Started Apr 2014; status: active, not recruiting.
02
Drugs
olaparib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02032823.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02032823.